News|Slideshows|March 25, 2021

8 Neuropsychiatric Symptoms and Treatments of Huntington Disease

Author(s)Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP, Monica Weber, MBA, MSSA, CCTP, LISW-S, Gilbert A. Masterson, MD

In approximately half of patients with Huntington disease, symptoms of depression, irritability/aggression, executive dysfunction, psychosis, cognitive decline, and dementia present long before progressive motor symptoms.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Patent Application Published: MDMA-N-Acylethanolamines for the Treatment of PTSD, Anxiety, and Eating Disorders

ByLeah Kuntz

August 24th 2026

Brain Function Biomarker Testing In Psychiatry With Universal Brain EEG

ByKazu Okuda, MD

August 21st 2026

FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder

ByLeah Kuntz

August 20th 2026

Neuropsychiatry in the News: Wearable Technology for Parkinson Disease, Ecopipam for Tourette Syndrome

ByLeah Kuntz

August 19th 2026

HLP003, Deuterated Psilocin, as an Adjunctive Therapy for Major Depressive Disorder

ByKen Kramer, PhD

August 17th 2026

Latest CME

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

8 Neuropsychiatric Symptoms and Treatments of Huntington Disease

Related Content

Patent Application Published: MDMA-N-Acylethanolamines for the Treatment of PTSD, Anxiety, and Eating Disorders

Brain Function Biomarker Testing In Psychiatry With Universal Brain EEG

FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder

Neuropsychiatry in the News: Wearable Technology for Parkinson Disease, Ecopipam for Tourette Syndrome

HLP003, Deuterated Psilocin, as an Adjunctive Therapy for Major Depressive Disorder

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Migraine and Psychiatric Comorbidities

Skin and Psych: Using Habit Loop Science to Interrupt the Itch-Scratch Cycle, With Judson Brewer, MD, PhD

FDA Clears First and Only Single-Biomarker Blood Test for Alzheimer Disease Assessment

Patent Application Published: MDMA-N-Acylethanolamines for the Treatment of PTSD, Anxiety, and Eating Disorders

Exploitation of Individuals With Psychosis